Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Blood (2022) 140 (Supplement 1): 3317–3319.

https://doi.org/10.1182/blood-2022-167677

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

Blood (2021) 138 (Supplement 1): 1242.

https://doi.org/10.1182/blood-2021-146606

Published: 2021

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2021-150281

Published: 2021

Journal Articles

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Blood (2021) 138 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2021-151287

Published: 2021

Journal Articles

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Blood (2021) 138 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2021-145917

Published: 2021

Journal Articles

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-140246

Published: 2020

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, MD, Eva Lengfelder, MD, Kerstin Schäfer-Eckart, MD, Katharina S Götze, MD, Michael Heuser, MD, Felicitas Thol, MD, Helmut R. Salih, MD, Mathias Hänel, MD, Karsten Spiekermann, Sonja Martin, MD, Sigrid Machherndl-Spandl, MD, Volker Kunzmann, MD, Andreas Jakob, MD, Hans-Joachim Tischler, MD, Dirk Niemann, MD, Joerg Mezger, MD, Tilmann Bochtler, MD, Stefan Krause, MD, Maike de Wit, MD, Claudia D. Baldus, MD, Richard Greil, MD, Jochen Greiner, Mark Ringhoffer, MD, Markus Radsak, MD, Mohammed Amen Wattad, MD, Wolff Schmiegel, MD, Elisabeth Koller, MD, Frank Heits, MD, Albrecht Reichle, MD, Stephan Kremers, MD, Andreas Hochhaus, MD, Nadezda Basara, MD, Dominik Wolf, MD, Martin Goerner, MD, Markus Schaich, MD, Harald Biersack, MD, Heinz Kirchen, MD, Thomas Kubin, MD, Gregor Aschauer, MD, Tanja Hesse, MD, Hartmut Link, MD PhD, Heinz Duerk, MDPhD, Dorit Kuerschner, MD, Walter Fiedler, MD, Bernd Hertenstein, MD, Martin Puttrich, Michael Kramer, M.Sc., Michaela Sauer, Wolfgang Hiddemann, Ulrich Duehrsen, MD, Hubert Serve, Christian Thiede, MD, Arnold Ganser, MD, Tim H. Brummendorf, MD, Konstanze Dohner, MD, Martin Bornhäuser, MD, Richard F. Schlenk, MD, Christoph Rollig, MD MSC, Hartmut Döhner, MD, Gerhard Ehninger, Peter Paschka, MD

Blood (2017) 130 (Supplement 1): 2618.

https://doi.org/10.1182/blood.V130.Suppl_1.2618.2618

Published: 2017

NARROW

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only